Biotech Movers: Lion Biotechnologies, XBiotech, Halozyme

Biotech Movers: Lion Biotechnologies, XBiotech, Halozyme


Shares of Lion Biotechnologies rose 18.9% to $7.25 in premarket trading on Friday. The San Carlos, Calif.-based firm said the first patient was dosed in the second cohort of its ongoing phase two study of LN-144 for the treatment of metastatic melanoma.



from Biotech News